46053-72-9

Basic information

• Product Name: 5-NITROISOINDOLINE
• Synonyms: 5-NITROISOINDOLINE;5-Nitro-2,3-dihydro-1H-isoindole;2,3-dihydro-5-nitro-1H-Isoindole;5-NITROISOINDOL;1H-Isoindole, 2,3-dihydro-5-nitro-
• CAS NO: 46053-72-9
• Molecular Formula: C₈H₈N₂O₂
• Molecular Weight: 164.16
• Mol File: 46053-72-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 293℃
• Flash Point: 131℃
• Appearance: /
• Density: 1.298
• Storage Temp.: 2-8°C
• PKA: 7.56±0.20(Predicted)
• CAS DataBase Reference: 5-NITROISOINDOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-NITROISOINDOLINE(46053-72-9)
• EPA Substance Registry System: 5-NITROISOINDOLINE(46053-72-9)

Safety Data

• Hazardous Substances Data: 46053-72-9(Hazardous Substances Data)

Usage

General Description

5-Nitroisoindoline is a chemical compound commonly used in scientific and pharmaceutical research. It falls under the category of Nitro Compounds and has the molecular formula C8H6N2O2. 5-nitroisoindoline is white to pale yellow in color and typically takes the form of a crystalline powder. It is characterized by its ability to engage in specific reactions due to the nitro group it possesses, making it valuable for producing various organic substances. However, caution must be exercised in handling this chemical due to its potential health hazards, which can cause skin and eye irritation, and harm to the respiratory system if inhaled. Safety measures, including wearing protective clothing, gloves, and eye protection, should also be observed.

InChI:InChI=1S/C8H8N2O2/c11-10(12)8-2-1-6-4-9-5-7(6)3-8/h1-3,9H,4-5H2

Upstream product

• 496-12-8 isoindoline 
• 832-51-9 1-(1,3-dihydro-2H-isoindol-2-yl)-2,2,2-trifluoroethanone 
• 1059172-96-1 2,2,2-trifluoro-1-(5-nitroisoindolin-2-yl)ethan-1-one 
• 127168-68-7 2,3-Dihydro-5-nitro-2-(phenylmethyl)-1H-isoindole 

Downstream Products

• 89-40-7 4-nitrophthalimide 
• 610-27-5 4-nitrophthalic acid 
• 944317-35-5 benzyl 5-nitro-1,3-dihydro-2H-isoindole-2-carboxylate 
• 722444-62-4 C₁₀H₁₂N₂O 
• 913000-09-6 (2,4-bis(benzyloxy)-5-isopropylphenyl)(5-nitroisoindolin-2-yl)methanone 
• 944317-39-9 2-benzyl 5-methyl 6-iodo-1,3-dihydro-2H-isoindole-2.5-dicarboxylate 
• 944317-38-8 2-benzyl 5-methyl 6-amino-1,3-dihydro-2H-isoindole-2.5-dicarboxylate 
• 944317-40-2 benzyl 5-(hydroxymethyl)-6-iodo-1,3-dihydro-2H-isoindole-2-carboxylate 
• 944317-37-7 benzyl 5-amino-6-iodo-1,3-dihydro-2H-isoindole-2-carboxylate 
• 944317-36-6 benzyl 5-amino-1,3-dihydro-2H-isoindole-2-carboxylate 
• 1264924-35-7 4-[(2,3-dihydro-1H-isoindol-5-yl)amino]-6-(4-methylphenyl)-5-pyrimidinol 
• 1264924-32-4 1,1-dimethylethyl 1,3-dihydro-5-[[5-methoxy-6-(4-methylphenyl)-4-pyrimidinyl]amino]-2H-isoindole-2-carboxylate 
• 264916-06-5 tert‐butyl 5‐amino‐2,3‐dihydro‐1H‐isoindole‐2‐carboxylate 
• 400727-63-1 tert-butyl 5-nitroisoindoline-2-carboxylate 

Relevant articles and documents

Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo

This study reports the synthesis of a series of 2-aroylisoindoline hydroxamic acids employing N-benzyl, long alkyl chain and acrylamide units as diverse linkers. In-vitro studies led to the identification of N-benzyl linker-bearing compound (10) and long

COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE

This disclosure concerns compounds and a method for modulating the activity of calcium ion channels, including Ca2+-induced (or Ca2+-activated) calcium release channels and conformationally coupled calcium release channels such as ryanodine receptors. Some of the compounds have a structure according to formula I, or a stereoisomer, tautomer, hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof.

PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.